Clinical Trial Update: LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC [Phase 2]

View source ↗

Summary

Phase 2 trial update for LUT014 aiming to reduce acneiform lesions caused by EGFR inhibitors in metastatic colorectal cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Egfr Inhibitor-induced Acneiform Lesions

Drugs mentioned

• LUT014

Snippet

Sponsor: Lutris Pharma Ltd. | Conditions: EGFRI Induced Acneiform Lesions | Phase 2 | Status: UNKNOWN